Agreement signedPublished 6 Mar 2025

Renovaro /
Predictive Oncology

Renovaro pursues acquisition of Predictive Oncology

Buy side: Renovaro
Buy sideRenovaro
Target: Predictive Oncology
TargetPredictive Oncology
Source · 6 Mar 2025Source-verified
Buy side: Renovaro
Buy sideRenovaro
Target: Predictive Oncology
TargetPredictive Oncology
01 / BuyerRenovaro
02 / TargetPredictive Oncology
Source-verified
01

What happened

Renovaro and Predictive Oncology extended their letter of intent for the proposed acquisition of Predictive Oncology’s capital stock. The extension moves the letter’s outside termination date to March 31, 2025.

The transaction remains subject to a definitive agreement and approval by Predictive Oncology stockholders.

02

The source

Everything on this page comes from the source below.

01
Source · Original source

Renovaro pursues acquisition of Predictive Oncology

This document is the source for the companies, stage and people on this page.

Source-verified
03

Timeline

Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.

  1. Published by the source

    The source this page is built from.

    Source-verified
  2. Also stated

    The source this page is built from.

    Source-verified

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Request an inviteAlready invited? Sign in

Carrywatch Pro is by invitation. An invite lets you buy Pro.